Rival obesity drugs seek out patients, and acceptance

July 1, 2013 by Landon Hall

Between 1999 and 2012, the Food and Drug Administration gave its blessing to exactly zero new weight-loss drugs. Then, starting in June of last year, the agency approved two such medications, in a span of 20 days.

The FDA didn't become a giddy cheerleader overnight. In fact, both drugs - Belviq, by Arena Pharmaceuticals Inc., and Qsymia, by Vivus Inc. - underwent a torturous path to approval because of concerns about their safety or effectiveness.

The drugs' approval is a statement on the nationwide epidemic of obesity more than anything else. More than one-third of American adults are obese. The FDA essentially acknowledged that, for a certain segment of the population, the remedies at hand - diet, exercise and, in extreme cases, bariatric surgery - aren't working.

"Obesity is such a huge problem, because it leads to so many other problems: , arthritis, diabetes, depression," said Dr. Rajesh Gulati, a clinical professor at UC Irvine's School of Medicine, and the medical director at the university's Weight Management Program. "Our health-care bills are going through the roof. If somebody is able to produce that , that guy is going to turn into a billionaire overnight.

"That is the motivating thing that keeps these companies producing these drugs."

Neither Belviq nor Qsymia is a magic pill. In fact, both have potential side effects severe enough that the FDA initially rejected them. The drugs are intended not for people who simply want to lose a few pounds but for those who meet the threshold of obesity: a body-mass index of at least 30 (a person who is 6 feet tall and weighs 221 pounds has a BMI of 30), or a BMI of at least 27, along with another weight-related problem such as , or . The drugs are meant to be used in conjunction with , like healthful eating and exercising.

But clinical trials have shown they're effective at helping people lose weight. The trick is convincing skeptical physicians, and patients, that they work well enough, and that they're safe enough, for long-term use.


Weight-loss aids have been around for generations, and in the 1950s, amphetamines became the rage because they sped up metabolism and produced weight loss. They also caused heart problems and created addicts.

In 1973, the FDA-approved drug fenfluramine was introduced in the United States and sold under the brand names Pondimin, Ponderax and Adifax. The drug increased the level of serotonin, a feel-good chemical in the body, producing a sensation of fullness. The initial problem was the effects didn't last. In the 1990s, the drug company American Home Products (which later became Wyeth) combined fenfluramine with phentermine, an appetite suppressant, and a new product, fen-phen, was born.

Fen-phen was the hot weight-loss drug of the day, and thousands of people shed pounds with it. But gradually, reports started coming in about elevated hypertension readings, then damage to heart valves. In a much-publicized case, Mary J. Linnen, 30, of Quincy, Mass., became ill only 24 days after taking fen-phen in the spring of 1996. She had been trying to lose weight so she could fit into just the right wedding dress. She died of heart problems on Feb. 22, 1997.

The drug was pulled from the market in September 1997, and the company settled thousands of lawsuits for $3.75 billion.

Others have come and gone: Sibutramine, marketed as Meridia, was withdrawn in 2010 because of high incidence of cardiovascular problems and strokes. Orlistat, marketed as Xenical (and in an over-the-counter version called Alli), was the last weight-loss drug approved by the FDA before the two new ones. It works in a different way, blocking the absorption of fats. But its distasteful side effects, including oily stools, make it unpalatable to many users.


Belviq (pronounced bell-VEEK), whose chemical name is lorcaserin, is made by San Diego-based Arena Pharmaceuticals and marketed by Japan's Eisai Inc. It was approved by the FDA on June 27, 2012, but an agency advisory panel had rejected it in 2010 because of safety concerns.

The most common side effect is headache, which occurred in about 18 percent of patients in clinical trials, compared to 11 percent with a placebo. But a larger concern is the same kind of heart-valve problems that plagued fenfluramine. The drug also could cause hallucinations if taken in higher dosages than prescribed.

The federal Drug Enforcement Agency classified the drug as a Schedule IV controlled substance, same as Qsymia. That means there's only a slight risk of abuse. But the concern over the drug's "hallucinogenic properties" delayed it getting to market, and it became available to the public only earlier this month.

How does Belviq work? It turns on a specific receptor that's normally stimulated by serotonin, bringing the sensation of satiety.

"The way we went about it is the recognition that serotonin is a very important hormonal system, one of the few mechanisms that can overcome this drive," said Dominic Behan, co-founder of Arena and the company's chief scientific officer. "The challenge is, there are many serotonin receptors: one we wanted to target, and we wanted to avoid the others, because if we stimulated them we'd run into side effects."

How well does it work? According to clinical trials, 47 percent of patients on the medication lost at least 5 percent of their body weight during the course of one to two years, compared with 23 percent of those on a placebo.


Qsymia (pronounced cue-SIMM-ee-uh) is a combination of phentermine, the safer "phen" component of fen-phen, and topiramate, an anti-seizure medication that also promotes weight loss. It's made by Mountain View-based Vivus.

Qsymia was approved by the FDA on July 17, 2012, three weeks after Belviq. But Qsymia got the jump on its rival because Belviq was subjected to the DEA's scheduling process. The head start didn't help Qsymia much, though, because it was slow to gain traction among physicians, and because insurers were reluctant to pay for it.

Since its September launch, Qsymia has cleared several hurdles: After a regulatory evaluation period, next month it will start being sold by pharmaceutical retailers; currently it's available only through mail-order. It's also prescribed in the Veterans Affairs system. And now 34 percent of private insurance policies cover it.

How does it work? The two drugs acting together suppress appetite, and since the separate components have been prescribed previously, it's a known commodity for physicians.

"Individually, we have years of data on them. That's always key in terms of the comfort level," said Dr. Christian Gastelum, an endocrinologist who treats obese patients in East Los Angeles and Whittier, Calif.

How well does it work? According to clinical-trial data, 70 percent of people taking it lost at least 5 percent of body weight, compared with only 20 percent on a placebo.


Although pregnant women should not take either drug, there's a particular danger of birth defects with Qsymia, which is part of the reason the FDA initially rejected it, in 2010 (back then it was called Qnexa; the FDA asked for the name to be changed to avoid confusion with other, similar-sounding branded drugs).

Vivus says women of child-bearing age must use contraception while on the drug, and should take a pregnancy test once a month while on it.

Meg Evans of Spring Valley, east of San Diego, says Qsymia has helped her.

She's 64, a former basketball player at Gonzaga University, and has struggled for years with her weight since giving birth to four daughters, now grown. At 5 feet 7, she weighed 230 pounds when she took part in Qnexa trials in 2008, and she lost 50 pounds. Once the trial ended, she gained back 20 pounds. But since she began taking Qsymia in January, she's lost 17 pounds.

"I fully believe diet and exercise are major factors," she said. "The Qsymia helps me stem my appetite, but it's not a magic bullet. I'm pretty sure I could take the Qsymia and still not lose any weight if I didn't watch what I eat and exercise."

Gulati, of the UCI School of Medicine, said he expects consumers to "make a beeline" for both drugs.

"People are fed up with weight, they'd like to lose weight, they've tried their best, and they're not succeeding," he said.

But he said the way the drugs work, interacting with the "normal metabolism of the body," is troubling. He says 5 percent weight loss, "in the grand scheme of things, is nothing."

Then there's that famously sketchy historical track record of weight-loss drugs.

"Fen-phen came out huge, then the side effects came in," he said. "I'm not saying every research is cooked up, but that's a lot of money companies are spending."

Also, he said: "These drugs have not been tested long enough on populations that are extremely sick, and that is a problem."



Made by: Arena Pharmaceuticals

Pronounced: bell-VEEK

Approved by the FDA: June 27, 2012


Made by: Vivus

Pronounced: cue-SIMM-ee-uh

Approved by the FDA: July 17, 2012

Explore further: Weight loss drug Belviq gets overdue US launch


Related Stories

Weight loss drug Belviq gets overdue US launch

June 7, 2013
Arena Pharmaceuticals says its weight loss drug Belviq will be available to U.S. patients beginning next week, nearly a year after the drug was officially approved by federal regulators.

FDA approves highly anticipated weight-loss pill

July 18, 2012
(AP) — The Food and Drug Administration on Tuesday approved a new weight loss drug from Vivus Inc. that many doctors consider the most effective therapy in a new generation of anti-obesity pills designed to help patients ...

US clears first new weight-loss pill in 13 years

June 27, 2012
(AP) — The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade.

US regulators to decide on new weight loss drug

July 17, 2012
US regulators were expected to decide Tuesday whether to approve the second new anti-obesity drug in 13 years, Qnexa, which studies have shown may help some people lose up to 10 percent of their body weight.

Weight loss drug added to diet and exercise improves blood sugar control

June 17, 2013
The new weight loss drug lorcaserin (Belviq) appears to improve blood sugar control in nondiabetic, overweight individuals, independent of the amount of weight they lose, a new study finds. The results will be presented Saturday ...

Diabetes drug may offer 'modest' weight loss for very obese teens

February 5, 2013
(HealthDay)—The drug Byetta, approved for adults with type 2 diabetes, appears to help severely obese teens lose some weight, a small study found.

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.